Ronald B. Postuma
1650 Cedar Ave
Montreal, QC, Canada
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 304 publications
Amyloid Co-Pathology and Clinical Heterogeneity of Parkinson's Disease.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: July 10, 2026
Brain-first and body-first subtypes of Lewy body disease.
Journal: Nature reviews. Neurology
Published: June 22, 2026
Discordance Between Striatal Dopaminergic Imaging and Motor Performances in REM Sleep Behavior Disorder.
Journal: Neurology open access
Published: March 30, 2026
Smartphone-derived digital motor measures to monitor progression in idiopathic REM sleep behavior disorder.
Journal: NPJ Parkinson's disease
Published: March 28, 2026
Case report of Parkinson's disease in isolated congenital anosmia with absent olfactory bulbs.
Journal: NPJ Parkinson's disease
Published: February 26, 2026
Shared Pathogenic Pathways Between REM Sleep Behavior Disorder and Neurodegenerative and Psychiatric Disorders.
Journal: medRxiv : the preprint server for health sciences
Published: February 12, 2026
Shared Pathogenic Pathways Between REM Sleep Behavior Disorder and Neurodegenerative and Psychiatric Disorders.
Journal: medRxiv : the preprint server for health sciences
Published: February 12, 2026
Reply to Comment on "Delayed Disease Onset Report in UK Biobank: Implications for Prodromal Studies in Parkinson's Disease".
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: February 12, 2026
Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers Initiative.
Journal: Annals of neurology
Published: February 11, 2026
Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson's disease.
Journal: NPJ Parkinson's disease
Published: February 06, 2026
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
Journal: Lancet (London, England)
Published: February 02, 2026
Last Updated: 09/26/2026